Switch theme
Sign up to access all valuation multiples
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
2017
196
LTM Revenue $2.9M
LTM EBITDA -$256M
$2.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Scholar Rock has a last 12-month revenue (LTM) of $2.9M and a last 12-month EBITDA of -$256M.
In the most recent fiscal year, Scholar Rock achieved revenue of n/a and an EBITDA of -$250M.
Scholar Rock expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Scholar Rock valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.9M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $2.5M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 86% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$256M | XXX | -$250M | XXX | XXX | XXX |
| EBITDA Margin | -8742% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$268M | XXX | -$252M | XXX | XXX | XXX |
| EBIT Margin | -9134% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$261M | XXX | -$246M | XXX | XXX | XXX |
| Net Margin | -8918% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Scholar Rock's stock price is $29.
Scholar Rock has current market cap of $2.8B, and EV of $2.5B.
See Scholar Rock trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.5B | $2.8B | XXX | XXX | XXX | XXX | $-2.47 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Scholar Rock has market cap of $2.8B and EV of $2.5B.
Scholar Rock's trades at n/a EV/Revenue multiple, and -9.8x EV/EBITDA.
Equity research analysts estimate Scholar Rock's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Scholar Rock has a P/E ratio of -10.5x.
See valuation multiples for Scholar Rock and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.8B | XXX | $2.8B | XXX | XXX | XXX |
| EV (current) | $2.5B | XXX | $2.5B | XXX | XXX | XXX |
| EV/Revenue | 836.6x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -9.6x | XXX | -9.8x | XXX | XXX | XXX |
| EV/EBIT | -9.2x | XXX | -9.7x | XXX | XXX | XXX |
| EV/Gross Profit | 974.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -10.5x | XXX | -11.2x | XXX | XXX | XXX |
| EV/FCF | -12.0x | XXX | -12.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialScholar Rock's last 12 month revenue growth is 2283%
Scholar Rock's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.3M for the same period.
Scholar Rock's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Scholar Rock's rule of X is -3034% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Scholar Rock and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2283% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -8742% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -32% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -3034% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Scholar Rock acquired XXX companies to date.
Last acquisition by Scholar Rock was XXXXXXXX, XXXXX XXXXX XXXXXX . Scholar Rock acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Scholar Rock founded? | Scholar Rock was founded in 2017. |
| Where is Scholar Rock headquartered? | Scholar Rock is headquartered in United States of America. |
| How many employees does Scholar Rock have? | As of today, Scholar Rock has 196 employees. |
| Who is the CEO of Scholar Rock? | Scholar Rock's CEO is Mr. David L. Hallal. |
| Is Scholar Rock publicy listed? | Yes, Scholar Rock is a public company listed on NAS. |
| What is the stock symbol of Scholar Rock? | Scholar Rock trades under SRRK ticker. |
| When did Scholar Rock go public? | Scholar Rock went public in 2018. |
| Who are competitors of Scholar Rock? | Similar companies to Scholar Rock include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Scholar Rock? | Scholar Rock's current market cap is $2.8B |
| What is the current revenue of Scholar Rock? | Scholar Rock's last 12 months revenue is $2.9M. |
| What is the current revenue growth of Scholar Rock? | Scholar Rock revenue growth (NTM/LTM) is 2283%. |
| What is the current EV/Revenue multiple of Scholar Rock? | Current revenue multiple of Scholar Rock is 836.6x. |
| Is Scholar Rock profitable? | Yes, Scholar Rock is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Scholar Rock? | Scholar Rock's last 12 months EBITDA is -$256M. |
| What is Scholar Rock's EBITDA margin? | Scholar Rock's last 12 months EBITDA margin is -8742%. |
| What is the current EV/EBITDA multiple of Scholar Rock? | Current EBITDA multiple of Scholar Rock is -9.6x. |
| What is the current FCF of Scholar Rock? | Scholar Rock's last 12 months FCF is -$204M. |
| What is Scholar Rock's FCF margin? | Scholar Rock's last 12 months FCF margin is -6944%. |
| What is the current EV/FCF multiple of Scholar Rock? | Current FCF multiple of Scholar Rock is -12.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
